Profile data is unavailable for this security.
About the company
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. It provides a comprehensive range of healthcare products, designed to meet the needs of patients across the United States. Its product categories include specialty medicines, sterile injectables, and generics. Its products include ADRENALIN CHLORIDE solution; ADREN ALIN; ALISKIREN tablets; ALLOPURINOL tablets, USP; ALPRAZOLAM ORALLY DISINTEGRATING tablets, USP CIV; ALVIMOPAN capsules; AMILORIDE HYDROCHLORIDE tablets, USP; APLISOL; ARGATROBAN injection; ASPIRIN & EXTENDED RELEASE DIPYRIDAMOLE capsules; AVEED; BACLOFEN TABLETS, USP; BENZTROPINE MESYLATE tablets, USP; BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE and TETRACYCLINE HYDROCHLORIDE capsules; BIVALIRUDIN injection; BREVITAL; BUPRENORPHINE HYDROCHLORIDE injection CIII; BUTALBITAL and ACETAMINOPHEN tablets; CALCITONIN SALMON injection, USP SYNTHETIC, and CANDESARTAN CILEXETIL tablets.
- Revenue in USD (TTM)1.92bn
- Net income in USD-2.60bn
- Incorporated2023
- Employees3.00k
- LocationEndo Inc1400 Atwater DriveMALVERN 19355United StatesUSA
- Phone+1 (484) 216-0000
- Fax+1 (302) 655-5049
- Websitehttps://www.endo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.33bn | 642.00 | 39.67 | 2.94 | 14.15 | 2.56 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.51bn | 1.60k | -- | 0.4217 | -- | 2.03 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.121 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.61bn | 154.00 | -- | 20.50 | -- | 29.15 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 597.40m | -15.51m | 1.69bn | 652.00 | -- | 1.82 | 24.31 | 2.83 | -0.2843 | -0.2843 | 10.86 | 16.90 | 0.3859 | 0.922 | 4.10 | 916,259.20 | -1.00 | 4.95 | -1.51 | 6.41 | 87.17 | 88.61 | -2.60 | 12.84 | 1.49 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.92bn | 58.00 | 20.47 | 2.38 | 14.57 | 16.27 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.93bn | 246.00 | 14.64 | 3.74 | 11.88 | 3.12 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.01bn | 497.00 | -- | 5.55 | -- | 7.55 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.08bn | 1.76k | 14.64 | 3.09 | 10.34 | 3.07 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 2.08bn | 167.00 | 32.67 | 3.70 | 20.61 | 5.05 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Endo Inc | 1.92bn | -2.60bn | 2.25bn | 3.00k | -- | -- | -- | 1.18 | -34.02 | -34.04 | 25.08 | -88.41 | -- | -- | -- | -- | -- | -- | -- | -- | 52.36 | -- | -135.65 | -- | 2.75 | 95.17 | 5.83 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.30bn | 7.70k | -- | -- | 21.57 | 0.9203 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 207.78m | 451.00k | 2.54bn | 314.00 | 5,472.80 | 10.85 | 470.90 | 12.24 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 3.05bn | 624.00 | -- | 19.84 | 639.69 | 10.77 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Data as of Jul 26 2024. Currency figures normalised to Endo Inc's reporting currency: US Dollar USD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Franklin Advisers, Inc.as of 31 May 2024 | 3.39m | 0.00% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 942.11k | 0.00% |
| Eaton Vance Managementas of 31 May 2024 | 38.02k | 0.00% |
| Amundi Asset Management US, Inc.as of 31 May 2024 | 8.79k | 0.00% |
| Eaton Vance Advisers International Ltd.as of 31 May 2024 | 3.65k | 0.00% |
| Virtus Fixed Income Advisers LLCas of 03 Jul 2024 | 339.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 05 Jul 2024Source: FactSet Research Systems Inc.
